|
Pathophysiology of Chemotherapy-Induced Cognitive Deficits in Juvenile Rats
|
5R01CA182284-05
|
$346,525
|
COLE, PETER
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Core Support for Cancer Center
|
5P30CA013330-45
|
$3,646,138
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Assay Development for NSD1 Methyltransferase Inhibitor Discovery
|
5R01CA191077-03
|
$312,244
|
KOLB, EDWARD
|
ALFRED I. DU PONT HOSP FOR CHILDREN
|
|
Nemours NCI Community Oncology Research Program (NCORP)
|
5UG1CA189958-04
|
$388,215
|
SANDLER, ERIC
|
ALFRED I. DU PONT HOSP FOR CHILDREN
|
|
Role of heat shock factors (Hsfs) in tumorigenesis
|
5R01CA132640-16
|
$270,000
|
MIVECHI, NAHID
|
AUGUSTA UNIVERSITY
|
|
Bay Area Tumor Institute NCORP
|
5UG1CA189817-04
|
$690,000
|
BAILEY, LISA
|
BAY AREA TUMOR INSTITUTE
|
|
(PQ5) Exploring the Biological Distinctions between HIV-related and Endemic Pediatric Kaposi Sarcoma in a Kaposi Sarcoma-Associated Herpesvirus-Endemic Region of Africa
|
1R21CA217137-01
|
$209,093
|
EL-MALLAWANY, NADER
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQB-1) Telomere maintenance defects and thyroid second cancer in childhood cancer survivors
|
5R01CA194473-03
|
$347,361
|
GRAMATGES, MARIA
|
BAYLOR COLLEGE OF MEDICINE
|
|
SPORE in Lymphoma
|
2P50CA126752-11
|
$3,097,657
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
ENHANCING T CELL THERAPY OF CANCER
|
5P01CA094237-15
|
$1,932,287
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Identifying Cell Stress Proteins that Predict Clinical Response in Pediatric AML
|
5R01CA164024-05
|
$319,474
|
HORTON, TERZAH
|
BAYLOR COLLEGE OF MEDICINE
|
|
White Matter Toxicity and Neurocognitive Outcomes in Pediatric Brain Tumor Patients Treated with Proton Beam Radiation Therapy
|
1R01CA221197-01
|
$633,169
|
KAHALLEY, LISA
|
BAYLOR COLLEGE OF MEDICINE
|
|
Cognitive Change after Proton RT vs. Photon or Surgery for Pediatric Brain Tumor
|
5R01CA187202-04
|
$577,030
|
KAHALLEY, LISA
|
BAYLOR COLLEGE OF MEDICINE
|
|
Mechanisms of KLF4 suppression in pediatric leukemia
|
1R01CA207086-01A1
|
$326,540
|
LACORAZZA, DANIEL
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQD-5) Patient derived orthotopic xenograft models for drug response prediction
|
5R01CA185402-04
|
$318,923
|
LI, XIONAN
|
BAYLOR COLLEGE OF MEDICINE
|
|
In Vivo Drug Testing of Pediatric CNS Tumors Using Patient Derived Orthotopic Xenograft Models
|
5U01CA199288-03
|
$578,693
|
LI, XIONAN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Identifying and targeting oncogenic Myc enhancer control in pediatric tumors
|
1R01CA215452-01
|
$362,569
|
LIN, CHARLES
|
BAYLOR COLLEGE OF MEDICINE
|
|
Identifying and targeting oncogenic Myc enhancer control in pediatric tumors
|
3R01CA215452-01S1
|
$14,309
|
LIN, CHARLES
|
BAYLOR COLLEGE OF MEDICINE
|
|
THE INITIATION AND REGULATION OF INFLAMMATION IN NEUROBLASTOMA
|
5R01CA116548-12
|
$249,637
|
METELITSA, LEONID
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S1
|
$118,333
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S2
|
$118,875
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S3
|
$122,250
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S4
|
$250,002
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-11
|
$3,253,119
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Pediatric Oncology Clinical Research Training Program
|
2K12CA090433-16
|
$810,000
|
POPLACK, DAVID
|
BAYLOR COLLEGE OF MEDICINE
|
|
Using Stat3 Signaling Profiles to Understand Chemotherapy Resistance in AML
|
5R01CA175026-04
|
$379,294
|
REDELL, MICHELE
|
BAYLOR COLLEGE OF MEDICINE
|
|
Targeting the G-CSF/STAT3 signaling pathway in neuroblastoma cancer stem cells
|
5R01CA174808-04
|
$326,348
|
SHOHET, JASON
|
BAYLOR COLLEGE OF MEDICINE
|
|
Dissecting the molecular and functional role of ILK in driving metastatic colonization and progression in Ewing sarcoma
|
1R03CA215940-01
|
$75,288
|
YUSTEIN, JASON
|
BAYLOR COLLEGE OF MEDICINE
|
|
Reducing risk of Anthracycline-related heart failure after childhood cancer
|
5R01CA196854-03
|
$610,389
|
ARMENIAN, SARO
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
City of Hope Lymphoma SPORE
|
3P50CA107399-10S1
|
$300,000
|
FORMAN, STEPHEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Targeted activation of autoimmune checkpoints in B cell malignancies
|
7R01CA157644-08
|
$410,875
|
M?SCHEN, MARKUS
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Metabolic basis of B cell lineage leukemia relapse
|
7R35CA197628-02
|
$1,036,898
|
M?SCHEN, MARKUS
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Pharmacological modulation of epigenetic changes in AML
|
5R01CA102031-12
|
$342,107
|
MARCUCCI, GUIDO
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
A novel VLP vaccine to prevent EBV infection and EBV - associated malignancies
|
1R21CA205106-01A1
|
$234,992
|
OGEMBO, JAVIER
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-34S1
|
$73,297
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-34S2
|
$124,999
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
5P30CA033572-34
|
$2,446,682
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
DF/HCC Kidney Cancer SPORE
|
5P50CA101942-13
|
$2,300,000
|
MCDERMOTT, DAVID
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Cohesin Mutations in Acute Myelogenous Leukemia
|
1R01CA204231-01A1
|
$391,588
|
RAO, SRIDHAR
|
BLOODCENTER OF WISCONSIN, INC.
|
|
Regulation of the LIN28/let-7 pathway in cancer
|
1R01CA211328-01
|
$404,888
|
GREGORY, RICHARD
|
BOSTON CHILDREN'S HOSPITAL
|
|
Role of m6A mRNA methylation in Neuroblastoma
|
1R21CA219352-01
|
$246,472
|
GREGORY, RICHARD
|
BOSTON CHILDREN'S HOSPITAL
|
|
Development of novel selective Rac inhibitors for refractory leukemias
|
5R01CA202756-02
|
$603,034
|
WILLIAMS, DAVID
|
BOSTON CHILDREN'S HOSPITAL
|
|
Functional characterization of the telomere repeat containing RNA, TERRA, in telomere maintenance
|
1R01CA214880-01
|
$376,294
|
FLYNN, RACHEL
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Molecular Mechanisms Regulating the Alternative Lengthening of Telomeres Pathway
|
5R01CA201446-02
|
$376,294
|
FLYNN, RACHEL
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Developing a translational pipeline for NF1-mutant malignancies
|
5U01CA202943-02
|
$380,076
|
CICHOWSKI, KAREN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Development of Novel Therapeutic Strategies in Human Leukemias
|
5P01CA066996-19
|
$2,248,452
|
EBERT, BENJAMIN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Pathogenesis and Treatment of NUT-Midline Carcinoma
|
5R01CA124633-10
|
$331,829
|
FRENCH, CHRISTOPHER
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Epstein-Barr Virus Nuclear Protein B Cell Growth Transformation
|
2R01CA047006-30
|
$532,500
|
Zhao, Bo
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Roles of Epstein-Barr virus nuclear antigens 2 and LP in B cell proliferation
|
5R01CA170023-05
|
$393,163
|
Zhao, Bo
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Characterizing TP53 and PPM1D mutations as resistance drivers to radiation therapy in Diffuse Intrinsic Pontine Gliomas
|
1R01CA219943-01
|
$502,615
|
BEROUKHIM, RAMEEN
|
BROAD INSTITUTE, INC.
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|